Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,

A global group of experts has suggested a new approach to diagnosing and treating obesity that does not rely solely on the much-contested body mass index (BMI).

Obesity is typically assessed by measuring someone's body mass index, but now researchers are calling for a more nuanced approach that could help with treatment

Body Mass Index, or BMI, has long been criticized as an unreliable method for measuring obesity — and now a group of experts is sharing new recommendations for how to use it.

An international commission made the case for focusing on body fat quantity and the illnesses people experience.

A new report says only using BMI to determine if a patient has obesity leads to under-diagnosing people who are ill and over-diagnosing people who don't currently deal with the negative health consequences of obesity.

By coincidence (they started before GLP -1 drugs were approved for slimming), a group of 56 doctors have just answered that question. This group, called the Lancet Commission, and organised by the journal of that name, have developed a better way of diagnosing obesity—one that distinguishes when it has become pathological.

Obesity, long determined by the flawed metric of BMI, should be diagnosed based on other measurements, experts argue.

The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug companies, including Rybelsus, another drug that works to combat diabetes and can lead to weight loss; Trelegy Ellipta, which treats chronic obstructive pulmonary disease and asthma; and Xtandi, which treats prostate cancer.

Former Trump administration health official Joe Grogan applauds Biden proposal that Medicare and Medicaid cover GLP-1 weight-loss drugs — but says subjecting Wegovy to price controls is a bad move.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).